J3-4313 — Final report
1.
The influence of imatinib active transport on the therapeutic outcome of chronic myeloid leukemia

Supervisorship (mentorship) of PhD candidates, young researchers. Young researcher Eva Kralj has successfully finished her postgraduate (doctoral) studies within time.

D.09 Tutoring for postgraduate students

COBISS.SI-ID: 271092224
2.
Imatinib intracellular uptake in leukocytes: method for determination and correlation with treatment success

To gain the insight into the intracellular imatinib uptake in granulocytes a very reliable two-stage sample concentration procedure was devised and coupled with a sensitive ultra-high performance liquid chromatography tandem mass spectrometry. The method has been applied to blood samples of 13 CML patients treated with imatinib and all the measured intracellular drug concentrations were within the validated range.

B.03 Paper at an international scientific conference

COBISS.SI-ID: 3536497
3.
Drug transporters and imatinib pharmacogenomics

The good bioavailability of imatinib is highly likely achieved by its active absorption from the intestine and its active elimination through the intestinal mucosa is mediated by a synergistic activity of organic cation transporter 1 in the basolateral membrane and the activity of two efflux proteins (P-glycoprotein and breast cancer resistant protein) in the apical membrane of enterocytes.

B.03 Paper at an international scientific conference

COBISS.SI-ID: 3460465
4.
Pharmacogenomics of tyrosine kinase inhibitors in chronic myeloid leukemia therapija

Imatinib, dasatinib and nilotinib are three tyrosine kinase inhibitors currently used to treat positive chronic myeloid leukemia (CML). The acquired mutations in the BCR-ABL1 kinase domain may contribute to resistance to tyrosine kinase inhibitors in CML patients.

B.04 Guest lecture

COBISS.SI-ID: 3315057